Literature DB >> 17473688

Prolonged allergen challenge in murine nasal allergic rhinitis: nasal airway remodeling and adaptation of nasal airway responsiveness.

Muneo Nakaya1, Makoto Dohi, Katsuhide Okunishi, Kazuyuki Nakagome, Ryoichi Tanaka, Mitsuru Imamura, Kazuhiko Yamamoto, Kimitaka Kaga.   

Abstract

BACKGROUND: Nasal airway remodeling exists in allergic rhinitis, but it appears to be far less extensive than in asthma. However, there has been little study about nasal airway remodeling and no study using mice models. It has been reported that airway hyperresponsiveness decreased after prolonged allergen challenge in a chronic murine asthma model together with the progression of remodeling. However, there has been no study of the relation of remodeling and airway responsiveness in nasal allergy. Therefore, we have undertaken this investigation to characterize nasal airway structural changes after prolonged allergen challenge and to examine the relationship between nasal airway hyperresponsivity and remodeling.
METHODS: We prepared murine allergic rhinitis for ovalbumin. Mice were subsequently challenged three times a week with ovalbumin from day 19 to days 53, 88, and 130. We examined allergen-induced nasal symptoms and objective nasal hyperresponsiveness using the enhanced pause system. Moreover, the pathologic changes were investigated after allergen challenge.
RESULTS: The extended allergen challenge protocol caused significant nasal airway remodeling. Specifically, remodeling was characterized by goblet cell hyperplasia and deposition of collagen in the submucosal area. Allergen-induced nasal hyperresponsiveness was first increased but gradually decreased in nasal symptoms and Penh after prolonged allergen challenge.
CONCLUSIONS: We have demonstrated that a remodeling of nasal mucosa in a murine allergic rhinitis model prolonged allergen exposure. Moreover, prolonged allergen exposure induced a reduction of nasal hyperresponsiveness together with a progression of nasal remodeling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473688     DOI: 10.1097/MLG.0b013e318033f9b0

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

1.  Airway responsiveness measured by barometric plethysmography in guinea pigs.

Authors:  Mario H Vargas; Bettina Sommer; Blanca Bazán-Perkins; Luis M Montaño
Journal:  Vet Res Commun       Date:  2010-07-13       Impact factor: 2.459

2.  Effectiveness of quercetin in an experimental rat model of allergic rhinitis.

Authors:  Mustafa Sagit; Halil Polat; Seren Gulsen Gurgen; Elife Berk; Sabri Guler; Mehmet Yasar
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-05-10       Impact factor: 2.503

3.  Role of angiogenic factors in airway remodeling in an allergic rhinitis murine model.

Authors:  Il Joon Moon; Dong-Young Kim; Chae-Seo Rhee; Chul Hee Lee; Yang-Gi Min
Journal:  Allergy Asthma Immunol Res       Date:  2011-11-01       Impact factor: 5.764

4.  Roles of periostin in symptom manifestation and airway remodeling in a murine model of allergic rhinitis.

Authors:  Dong Gu Hur; Roza Khalmuratova; Seong-Ki Ahn; Young-Sool Ha; Yang-Gi Min
Journal:  Allergy Asthma Immunol Res       Date:  2012-06-08       Impact factor: 5.764

5.  Nasal epithelial cells can act as a physiological surrogate for paediatric asthma studies.

Authors:  Surendran Thavagnanam; Jeremy C Parker; Michael E McBrien; Grzegorz Skibinski; Michael D Shields; Liam G Heaney
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

6.  Effects of topical intranasal doxycycline treatment in the rat allergic rhinitis model.

Authors:  Mehmet Ozgür Avincsal; Seda Ozbal; Ahmet Omer Ikiz; Cetin Pekcetin; Enis Alpin Güneri
Journal:  Clin Exp Otorhinolaryngol       Date:  2014-05-21       Impact factor: 3.372

7.  Leptin Regulated ILC2 Cell through the PI3K/AKT Pathway in Allergic Rhinitis.

Authors:  Qingxiang Zeng; Xi Luo; Yiquan Tang; Wenlong Liu; Renzhong Luo
Journal:  Mediators Inflamm       Date:  2020-03-07       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.